Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.64 |
| ▸ | DRD3 | P35462 | 13/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855317 | 0.93 | DRD2 (0.73) | DRD2DRD3SLC6A4ADRB1DRD4 | |
| SCHEMBL3843723 | 0.93 | DRD2 (0.73) | DRD2DRD3SLC6A4ADRB1DRD4 | |
| SCHEMBL25106928 | 0.81 | DRD2 (0.68) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL22303331 | 0.81 | DRD2 (0.79) | DRD2DRD3SLC6A4ADRB1DRD4 | |
| SCHEMBL12736175 | 0.81 | HTR1A (0.56) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL22302295 | 0.80 | DRD2 (0.69) | DRD2DRD3SLC6A2SLC6A4DRD4 | |
| SCHEMBL18073600 | 0.80 | DRD2 (0.77) | DRD2DRD3SLC6A4ADRB1DRD4 | |
| SCHEMBL28475732 | 0.79 | DRD2 (0.75) | DRD2DRD3SLC6A4ADRB1DRD4 | |
| SCHEMBL20672353 | 0.78 | DRD2 (1.00) | DRD2DRD3SLC6A4ADRB1DRD4 | |
| SCHEMBL22302843 | 0.78 | DRD2 (0.77) | DRD2DRD3SLC6A4ADRB1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024072930-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-04-04 | — | — | WO | disclosed |